Growth Metrics

Acro Biomedical (ACBM) Asset Writedowns and Impairment (2023)

Acro Biomedical's quarterly Asset Writedowns and Impairment came in at $480000.0 in Q3 2023.

Acro Biomedical has reported Asset Writedowns and Impairment for 1 years, with the latest figure at $480000.0 in Q3 2023.

  • For the quarter ending Q3 2023, Asset Writedowns and Impairment changed N/A year-over-year to $480000.0; the trailing twelve-month figure through Dec 2024 stood at $480000.0 (changed N/A YoY), and the FY2023 full-year result was $480000.0, changed N/A from the prior year.
  • Asset Writedowns and Impairment for Q3 2023 stood at $480000.0.
  • The five-year high for Asset Writedowns and Impairment was $480000.0 in Q3 2023, with the low at $480000.0 in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn -
2 Berto Acquisition 316.66 Mn 316.66 Mn -
3 Centurion Acquisition 311.94 Mn 311.94 Mn -
4 Churchill Capital Corp IX 311.36 Mn 311.36 Mn -
5 Agriculture & Natural Solutions Acquisition 301.94 Mn 301.94 Mn -
6 Siddhi Acquisition Corp (Cayman Islands) 286.76 Mn 286.76 Mn -
7 Bold Eagle Acquisition 276.06 Mn 276.06 Mn -
8 Cartesian Growth Corp III 270.68 Mn 270.68 Mn -
9 Oyster Enterprises II Acquisition 266.84 Mn 266.84 Mn -
10 Acro Biomedical - - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2023 480,000.00
Sep 30, 2023 480,000.00